Becker muscular dystrophy

News

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

Santhera seeks speedy FDA review of Duchenne drug vamorolone

Santhera has completed a rolling application for its Duchenne muscular dystrophy (DMD) therapy vamorolone in the US, setting up a possible approval and launch in the latter half of 2023.

Oncology

pharmaphorum podcast Episode 286, Kate Estep, Flatiron Health

Closing the global evidence gap in oncology, with Flatiron H...

Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Securing your ROI: Turning post-acquisition integration into...

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.

Becker muscular dystrophy

Editor's Picks